THERAPEUTIC MODALITIES Archives

Supporting Discovery of mRNA Drugs

Unlike conventional protein-targeted therapies, which often provide only transient effects, nucleic acid therapeutics have the potential for long-lasting effects and...

Advanced Conjugate Delivery Systems for Oligonucleotides

Oligonucleotide therapeutics represent a transformative treatment modality with demonstrated potential across metabolic disorders, CNS diseases, muscular dystrophies, and a broad...

Peptide Early Discovery Services

Peptide drugs, composed of short chains of amino acids, represent a promising class of therapeutics with unique advantages over traditional...

mTOR Inhibition Enhances Targeted Protein Degradation Efficacy

Targeted protein degradation (TPD) approaches, including molecular glue degraders (MGDs) and proteolysis targeting chimeras (PROTACs), can overcome traditional occupancy-based inhibitor...

HTS Platform to Advance Molecular Glue Discovery

Despite major advances in small molecule drug development, most disease-relevant proteins remain beyond the reach of conventional therapeutics. Molecular glues...

R&D Strategies for T Cell Engager Drugs

From hematologic malignancies to solid tumors Introduction: Amid a surge of advancements in immunotherapy, T cell engager (TCE) therapy has...

Screening Strategies for Molecular Glue Discovery

Molecular glues are molecules that can encourage two proteins to interact when they otherwise may not. As a consequence, they...

Antibody-Targeted Precision Medicines

Antibody-targeted therapies—including antibody-drug conjugates (ADCs), antibody-oligonucleotide conjugates (AOCs), and degrader-antibody conjugates (DACs)—are reshaping precision medicine by enabling highly selective delivery...

Evolution of AAV Therapy: Challenges, Breakthroughs, and Future Directions

Overview of AAV Gene Therapy: Evolution and Current Landscape Adeno-associated virus (AAV) is a non-enveloped, replication-defective single-stranded DNA virus belonging...

Knowledge Library